Portugal – Antineoplastic and immunomodulating agents – 251G001449 - C.Central Medicamentos 2025 -1729/2025- NATALIZUMAB
Tender Description
NATALIZUMAB INJ 20MG/ML AMP 15 ML
Unlock Full Tender Insight
Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.
It's free to get started. No credit card required.